Esperion Therapeutics, Inc. announced that the Hart-Scott-Rodino Antitrust Improvements Act waiting period expired on June 15, 2026, regarding its merger with Essence Parent Inc. The transaction remains subject to other closing conditions, including stockholder approval at a special meeting scheduled for July 8, 2026. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines.
